- Digital health company ResApp (RAP) saw its diagnostic technology integrated with Alodokter and Doctors on Demand over the December quarter
- ResApp is now live on telehealth platforms in Europe, Australia and Indonesia
- However, the main focus on the quarter has been the company’s COVID-19 program, where it aims to create a program capable of detecting the virus through a cough on a smartphone
- Recruitment in India and the United States has been ongoing throughout the quarter
- On the market this morning, ResApp is up 13.7 per cent and trading at 5.8 cents per share
Over the December quarter, ResApp (RAP) saw its diagnostic technology integrated with Alodokter and Doctors on Demand.
During the period, the digital health company worked closely with Alodokter and Doctors on Demand to complete the integration of its ResAppDx technology into their telehealth platforms.
Alodokter is Indonesia’s largest telehealth provider, connecting more than 50,000 doctors and 1500 clinics with millions of Indonesian patients.
Doctors on Demand offers both direct-to-consumer and business-to-business offerings for virtual primary care in Australia with leading Australian corporates as its customers.
ResApp is now live on telehealth platforms in Europe, Australia and Indonesia.
In November, the company signed a three year non-exclusive licensing agreement with Janssen Pharmaceutica, one of the pharmaceutical companies of Johnson & Johnson, for the use of its ResAppDx technology in a respiratory syncytial virus clinical trial.
“In this quarter we finalised the integration of ResAppDx into two additional telehealth platforms — Alodokter in Indonesia and Doctors on Demand in Australia,” CEO and Managing Director Tony Keating said.
“We were excited to see these two integrations launch in January. We now have ResAppDx being used by a growing number of patients and doctors in Europe, Australia and Asia. It’s through this use that we will grow trust and confidence in our technology which will drive further adoption.”
However, the main focus of the quarter was the company’s COVID-19 program, with ResApp continuing to recruit for its studies in India and US.
These studies aim to collect cough sounds and polymerase chain reaction
COVID-19 test results to train an algorithm to instantly identify COVID-19 using only a
smartphone.
“We are very pleased with quality of the cough recordings and clinical data obtained from our clinical studies in India and the US,” Dr Keating said.
“We believe that the combination of this data with our pre-COVID-19 Australian data
gives us a unique advantage in developing the only truly COVID-19 specific cough sound-based algorithm for use on a smartphone. We are excited about the progress we’ve made in algorithm development and are looking forward to sharing our results in the near future.”
Customer receipts for the quarter increased to $124,000, which is a jump from the first quarter’s $7000.
Overall cash decrease was just over $1 million, down from $2.1 million in the first quarter, with net cash used in operating activities totalling $969,000, down from $2.1 million in the previous quarter.
At the end of the period, ResApp had a cash balance of $3.4 million.
On the market this morning, ResApp was up 13.7 per cent and is trading at 5.8 cents per share at 11:15 am AEDT.